Mejora a largo plazo de sodio sérico byThe antagonista de los receptores V2 satavaptanin pacientes con cirrosis andhyponatraemia

Autores
Categoría Estudio primario
RevistaHepatology
Año 2007
Cargando información sobre las referencias
Aquaretics improve hyponatremia in cirrhotic patients, but their effect at long term is not known.After a first 14-days double-blind placebo-controlled study, patients were re-randomised to receive either satavaptan (5-50mg/d) or placebo to maintain natremia between 135 and 145 mmol/l.After the first study,when stopping satavaptan,sodium returned rapidly to low rate (from 134 to 128 mmol/l).With satavaptan, natremia improvement is maintained at long term (from 131 to 136 mmol/l at 40 weeks of treatment) without serious adverse events
Epistemonikos ID: c5d7d1c7a210608bd6bb5829f55a1e7b70053574
First added on: May 22, 2015